ArticleBMC medical imaging2025
An ultrasound-based model for predicting the response to neoadjuvant chemotherapy in early stage triple negative breast cancer patients.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe accurate identification of patients with triple negative breast cancer (TNBC) likely to achieve pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) holds significant clinical value. The aim of this study was to establish a prediction model that incorporate clinical data and ultrasound features to predict pCR among TNBC patients as early as possible after the initial two NAC cycles.
methodsFrom January 2016 to December 2021, a total of 262 patients were recruited and divided into training and validation groups at a 7:3 ratio. Both univariate and multivariate logistic regression analyses were conducted to identify independent factors predicting pCR in the training group. Subsequently, a nomogram integrating the predictive factors was established and applied to the validation group. The performance of this model was assessed based on its discrimination, calibration and clinical utility.
resultsThe nomogram that incorporated patient age, clinical T stage, posterior echo enhancement and tumor volume reduction showed robust performance. It achieved an area under curve (AUC) of 0.818, and recorded sensitivity, specificity, and accuracy of 65.2%, 82.5%, and 75.0% respectively in the training group. In the validation group, the model scored an AUC of 0.776, with sensitivity, specificity, and accuracy of 85.7%, 66.7%, and 73.4%, respectively. The decision curve analysis further indicated that the model provided more benefit than standard treat-all or treat-none approaches in predicting pCR.
conclusionThis prediction model may assist in predicting pCR to NAC among patients with TNBC, enabling an optimal treatment management in clinical practice.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.